Notícias e Atividades da Oncolytics Biotech

Oncolytics Biotech é uma empresa listada sob o símbolo ONC (CA).

Veja o organograma con seus 12 executivos principais

Biografias mais buscadas da Oncolytics Biotech

• Wayne Pisano, Chairman and Interim Chief Executive Officer
• Bernd Seizinger, Director
• Jonathan Rigby, Director

Criar um alerta
para seguir os movimentos de executivos da Oncolytics Biotech.

Oncolytics Biotech possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Oncolytics Biotech

• Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data | Oncolytics Biotech Inc.
• Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data | Oncolytics Biotech Inc.
• Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium | Oncolytics Biotech Inc.
• Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort | Oncolytics Biotech Inc.
• Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights | Oncolytics Biotech Inc.
• Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights | Oncolytics Biotech Inc.
• Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path | Oncolytics Biotech Inc.
• Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study | Oncolytics Biotech Inc.
• Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September | Oncolytics Biotech Inc.
• Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights | Oncolytics Biotech Inc.
• View more press releases Close

Redes sociais sobre Oncolytics Biotech

• Oncolytics Biotech na Wikipedia, Google News e Yahoo Finance
• Oncolytics Biotech na LinkedIn, Twitter e YouTube